ARS PHARMACEUTICALS
ARS Pharmaceuticals is a stealth pharmaceutical company that developed a novel intranasal epinephrine spray with a unique absorption technology that could be easy-to-use, convenient, and more reliable for patients and loved ones at risk of severe allergic reactions to food, medications and insect bites that could lead to life-threatening anaphylaxis.
ARS PHARMACEUTICALS
Industry:
Biopharma Health Care Medical Pharmaceutical
Founded:
2015-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.ars-pharma.com
Total Employee:
11+
Status:
Active
Contact:
858-335-1300
Total Funding:
75 M USD
Technology used in webpage:
Euro CrUX Top 50m Common Name Invalid Amazon Route 53 Slider Revolution Elementor Pro Google Cloud Global Multi-Region Mailgun EmbedPress FEEDZY RSS Feeds
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Alara Gateway
The medical imaging gateway built for cloud-native workflows
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Marius Pharmaceuticals
Marius Pharmaceuticals is a biopharmaceutical company that brings novel treatments to a range of diseases with unmet medical needs.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-11-08 | Silverback Therapeutics | Silverback Therapeutics acquired by ARS Pharmaceuticals | N/A |
Investors List
SR One
SR One investment in Series D - ARS Pharmaceuticals
Deerfield
Deerfield investment in Series D - ARS Pharmaceuticals
RA Capital Management
RA Capital Management investment in Series D - ARS Pharmaceuticals
Deerfield
Deerfield investment in Series C - ARS Pharmaceuticals
Key Employee Changes
Official Site Inspections
http://www.ars-pharma.com Semrush global rank: 594.06 K Semrush visits lastest month: 54.23 K
- Host name: 249.110.215.35.bc.googleusercontent.com
- IP address: 35.215.110.249
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "ARS Pharmaceuticals"
ARS Pharma – Developing Biotechnology
At ARS Pharma, we are committed to developing patient-friendly treatments to address serious issues related to needle-related risks, device portability and ease of use. Our innovative …See details»
Leadership - ARS Pharma
Sarina Tanimoto, M.D., M.B.A., is our co-founder and has served as our Chief Medical Officer since 2018, a position she has functionally served in since 2015.From 2015 to 2018, Dr. …See details»
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 …
1 day ago On Wednesday, January 15, 2025, at 7:30am PT, Richard Lowenthal, President and CEO of ARS Pharma, will present a company overview at the 43 rd Annual J.P. Morgan …See details»
ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) Delaware. 81-1489190 (State or other jurisdiction of. incorporation or organization) (I.R.S. Employer. …See details»
ARS Pharmaceuticals Announces Exclusive Agreement with Global …
Nov 11, 2024 ARS Pharmaceuticals, Inc. Agreement leverages ALK’s global footprint in developing and commercializing innovative allergy products. ARS Pharma to receive an …See details»
Investors - ARS Pharmaceuticals
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting October 24, 2024 ARS …See details»
ARS Pharma seeks approval for epinephrine spray in Canada and UK
6 days ago ARS Pharma co-founder, president and CEO Richard Lowenthal said: “Building upon the approval of neffy in the US and Europe for the emergency treatment of severe allergic …See details»
Richard Lowenthal - ARS Pharma
Richard Lowenthal, M.S., MSEL, is our co-founder and has served as our President and a member of our Board of Directors since our inception in 2015.He also served as our Chairman from 2015 through 2018 and has served as our …See details»
ARS Pharmaceuticals - Crunchbase Company Profile
ARS Pharmaceuticals is a stealth pharmaceutical company that developed a novel intranasal epinephrine spray with a unique absorption technology that could be easy-to-use, convenient, and more reliable for patients and loved ones at …See details»
ARS Pharmaceuticals Files for Approval of neffy® in Canada and …
Jan 6, 2025 ARS Pharma retains all U.S. rights for neffy and has existing licensing partnerships in China, Japan, Australia and New Zealand with Pediatrix Therapeutics, Alfresa Pharma, and …See details»
ARS Pharmaceuticals Files for Approval of neffy® in Canada and …
Jan 6, 2025 ARS Pharma is also evaluating its intranasal epinephrine technology for the treatment of acute flares in patients with chronic urticaria, with plans to begin a Phase 2b …See details»
ALK licenses rights to neffy - NLS - nordiclifescience.org
Nov 11, 2024 Furthermore, ARS Pharma may receive up to USD 320 million (DKK 2.2 billion) related to regulatory and commercial milestones, potentially over the next 15+ years as well as …See details»
ARS Pharma - Craft
Oct 29, 2024 ARS Pharma is a pharmaceutical company developing solutions that protect patients from severe allergic reactions that could lead to anaphylaxis. It offers ARS-1, an …See details»
Careers - ARS Pharma
ARS Pharma believes in Equal Opportunity for all and is committed to ensuring all individuals, including individuals with disabilities, have an opportunity to apply for those positions that they …See details»
Working at ARS Pharmaceuticals - Zippia
Mar 14, 2024 ars-pharma.com. Organization Type. Private. Social Media. ARS Pharmaceuticals is a stealth pharmaceutical company that developed a novel intranasal epinephrine spray with …See details»
ARS Pharmaceuticals files for approval of neffy in Canada, U.K.
Jan 6, 2025 ARS Pharmaceuticals (SPRY) announced that ARS Pharma has filed for approval of neffy 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy, on …See details»
Contact Us - ARS Pharma
11682 El Camino Real, Suite 120 San Diego, CA 92130. Main Phone: 858-771-9307See details»
ARS Pharm - Overview, News & Similar companies | ZoomInfo.com
Apr 17, 2024 ARS Pharm operates as a pharmaceutical company. The Company develops an intranasal epinephrine spray with a unique absorption technology to save pa tients from …See details»
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 …
13 hours ago ARS Pharmaceuticals, Inc. Preliminary fourth quarter neffy ® net product revenue of approximately $6.5 million. Preliminary cash, cash equivalents and short-term investments …See details»
Pipeline - ARS Pharma
ARS Pharma is currently advancing our innovative nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria. URTICARIA …See details»